Breaking News Instant updates and real-time market news.

OBSV

ObsEva

$17.21

2.68 (18.44%)

07:48
06/19/18
06/19
07:48
06/19/18
07:48

ObsEva price target raised to $31 from $23 at BMO Capital

BMO Capital analyst Peter Lawson raised his price target on ObsEva to $31 following the positive OBE2109 EDELWEISS data in endometriosis, saying the results "confirm comparable high dose efficacy to leader Elagolix" with better balanced pain benefit. Lawson adds that the 5-month bone data expected in Q4 of this year will further support the OBE2109 preferable profile, leading to the initiation of a Phase 3 endometriosis study in Q1 of 2019. The analyst is also positive on additional upside coming from the Nolasiban live birth rate data and OBE022 phase 2 read-out in Q4, keeping his Outperform rating on ObsEva.

  • 20

    Jun

OBSV ObsEva
$17.21

2.68 (18.44%)

06/18/18
BMOC
06/18/18
NO CHANGE
Target $31
BMOC
Outperform
ObsEva positive EDELWEISS data de-risks Phase 3 studies, says BMO Capital
BMO Capital analyst Do Kim raised the price target for ObsEva to $31 from $23, while reiterating an Outperform rating on the shares, following positive OBE2109 EDELWEISS data in endometriosis. He believes the data confirms OBE2109 benefit and further de-risks Phase 3 studies in uterine fibroid. The analyst also raised his probability of success to 70% and said he expects 6-month bone data in Q4 to further support OBE2109 preferable profile, and initiation of Phase 3 endometriosis study in Q1. In the interim, additional upside could come from Nolasiban live birth rate data and OBE022 Phase 2 data in Q4.
06/18/18
BMOC
06/18/18
NO CHANGE
Target $31
BMOC
Outperform
ObsEva price target raised to $31 from $23 at BMO Capital
BMO Capital analyst Do Kim raised the price target on ObsEva to $31 from $23 after the company reported 12-week results from its Phase 2b clinical trial of linzagolix for the treatment of endometriosis-associated pain. Kim maintains an Outperform rating on ObsEva shares.
06/12/18
BMOC
06/12/18
INITIATION
Target $23
BMOC
Outperform
ObsEva initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated ObsEva with an Outperform rating and a price target of $23, saying the company's OBE2109 offers "the best drug profile among GnRH antagonists" which will allow it to capture a "meaningful market share in uterine fibrosis and endometriosis". The analyst adds that ObsEva's Nolasiban is underappreciated despite the positive Phase 3 data, and the live birth results in Q4 may lead to investors' reassessment of the treatment.
02/28/18
HCWC
02/28/18
NO CHANGE
Target $27
HCWC
Buy
ObsEva target raised to $27 on positive nolasiban data at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva to $27 citing the positive top-line data from the first pivotal Phase 3 trial of its most advanced clinical-stage candidate, nolasiban. The analyst views the results as statistically significant and clinically meaningful. He reiterates a Buy rating on ObsEva.

TODAY'S FREE FLY STORIES

NFLX

Netflix

09:28
10/17/18
10/17
09:28
10/17/18
09:28
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TPR

Tapestry

$44.48

1.39 (3.23%)

09:27
10/17/18
10/17
09:27
10/17/18
09:27
Upgrade
Tapestry rating change  »

Tapestry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

NFLX

Netflix

$346.40

13.29 (3.99%)

09:26
10/17/18
10/17
09:26
10/17/18
09:26
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PVTL

Pivotal Software

$19.94

1.44 (7.78%)

09:25
10/17/18
10/17
09:25
10/17/18
09:25
Hot Stocks
Pivotal Software weakness attributed to lock-up expiration »

Shares of Pivotal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$158.81

5.25 (3.42%)

09:25
10/17/18
10/17
09:25
10/17/18
09:25
Periodicals
Facebook Watch lands The Real World from MTV, Deadline reports »

Facebook Watch will now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

COOP

Mr. Cooper

$15.22

-0.39 (-2.50%)

09:24
10/17/18
10/17
09:24
10/17/18
09:24
Recommendations
Mr. Cooper analyst commentary  »

Mr. Cooper price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSX

Diana Shipping

$3.95

0.07 (1.80%)

, GLNCY

Glencore

$0.00

(0.00%)

09:23
10/17/18
10/17
09:23
10/17/18
09:23
Hot Stocks
Diana Shipping reports continuation of time charter contract with Glencore »

Diana Shipping (DSX)…

DSX

Diana Shipping

$3.95

0.07 (1.80%)

GLNCY

Glencore

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEON

Neonode

$2.90

0.355 (13.95%)

09:23
10/17/18
10/17
09:23
10/17/18
09:23
Hot Stocks
Neonode regains compliance with Nasdaq minimum bid price requirement »

Neonode received a letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$2.89

0.195 (7.25%)

09:23
10/17/18
10/17
09:23
10/17/18
09:23
Hot Stocks
Kadmon announces FDA breakthrough therapy designation granted to KD025 »

Kadmon announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$145.02

3.9 (2.76%)

09:23
10/17/18
10/17
09:23
10/17/18
09:23
Recommendations
IBM analyst commentary  »

IBM price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

GPN

Global Payments

$119.87

4.42 (3.83%)

09:22
10/17/18
10/17
09:22
10/17/18
09:22
Recommendations
Global Payments analyst commentary  »

Global Payments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

HD

Home Depot

$193.61

2.51 (1.31%)

, LOW

Lowe's

$105.97

1.31 (1.25%)

09:21
10/17/18
10/17
09:21
10/17/18
09:21
Downgrade
Home Depot, Lowe's rating change  »

Home Depot, Lowe's…

HD

Home Depot

$193.61

2.51 (1.31%)

LOW

Lowe's

$105.97

1.31 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

GWW

Grainger

$280.03

-38.35 (-12.05%)

09:20
10/17/18
10/17
09:20
10/17/18
09:20
Recommendations
Grainger analyst commentary  »

Grainger selloff may be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

HAIR

Restoration Robotics

$1.79

-0.04 (-2.19%)

09:19
10/17/18
10/17
09:19
10/17/18
09:19
Hot Stocks
Restoration Robotics announces results of ARTAS iX case study at ASDS »

Restoration Robotics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 27

    Nov

IBM

IBM

$145.02

3.9 (2.76%)

09:18
10/17/18
10/17
09:18
10/17/18
09:18
Technical Analysis
Technical Take: IBM hits fresh 52-week low after earnings disappoint »

At time of writing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 03

    Mar

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
10/17/18
10/17
09:18
10/17/18
09:18
Options
Overnight activity included 287 trades in SPX and 3 trades in VIX »

287 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$18.88

0.76 (4.19%)

09:17
10/17/18
10/17
09:17
10/17/18
09:17
Recommendations
Marvell analyst commentary  »

Marvell management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIFI

Boingo Wireless

$33.43

1.84 (5.82%)

09:17
10/17/18
10/17
09:17
10/17/18
09:17
Recommendations
Boingo Wireless analyst commentary  »

Boingo Wireless price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ABT

Abbott

$70.94

2.22 (3.23%)

09:16
10/17/18
10/17
09:16
10/17/18
09:16
Earnings
Breaking Earnings news story on Abbott »

Abbott sees FY18 sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ABT

Abbott

$70.94

2.22 (3.23%)

09:16
10/17/18
10/17
09:16
10/17/18
09:16
Earnings
Breaking Earnings news story on Abbott »

Abbott sees Q4 sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ODP

Office Depot

$2.85

0.005 (0.18%)

, WPP

WPP

$69.83

0.59 (0.85%)

09:15
10/17/18
10/17
09:15
10/17/18
09:15
Hot Stocks
Office Depot expands marketing agency of record with WPP »

Office Depot (ODP) and…

ODP

Office Depot

$2.85

0.005 (0.18%)

WPP

WPP

$69.83

0.59 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QRTEA

Qurate Retail

$21.94

0.32 (1.48%)

09:15
10/17/18
10/17
09:15
10/17/18
09:15
Hot Stocks
Qurate Retail announces long-term iniatitives »

Qurate Retail Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

  • 14

    Nov

CREE

Cree

$37.56

2.53 (7.22%)

09:14
10/17/18
10/17
09:14
10/17/18
09:14
Recommendations
Cree analyst commentary  »

Cree focus on tightening…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGI

Renewable Energy

$29.86

1.31 (4.59%)

09:14
10/17/18
10/17
09:14
10/17/18
09:14
Recommendations
Renewable Energy analyst commentary  »

Renewable Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 14

    Nov

  • 15

    Nov

  • 16

    Nov

PE

Parsley Energy

$29.70

0.7 (2.41%)

09:14
10/17/18
10/17
09:14
10/17/18
09:14
Downgrade
Parsley Energy rating change  »

Parsley Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.